Chinese experience goes global——Professor Zhao Weilai shared valuable experience of CAR-T treatment at the APBMT conference

The sky is clear and fresh, and the golden breeze is refreshing
.

October 14-17, 2021, in this golden season, the 26th Asia-Pacific Bone Marrow Transplant Conference (APBMT) will be held as scheduled.
Many top scholars at home and abroad will gather online to focus on academic frontiers and discuss academic development.
It shines in the great cause of promoting the active development of global medicine and better safeguarding the health of the people of the world
.

In the Kite academic session on the 16th, many international experts gave academic lectures and exchanges on the role of CAR-T in hematological tumors.
The participating experts and scholars included Professor Jim Kochenderfer from the National Cancer Center of Maryland, USA, and Moffitt, Florida, USA Professor Frederick Locke from the Cancer Center; Professor Ana Sureda from the Catalan Cancer Institute in Barcelona, ​​Spain; Professor Irit Avivi from the Sourasky Medical Center in Tviraf, Israel; Professor Robin Sanderson from King's College Hospital, London, UK; Professor Caron Jacobson, Dana-Farber Cancer Institute, Boston, USA; Paris, France Professor Mohamad Mohty from St.
Anthony's Hospital and Professor Zhao Weilai from Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China
.

Professor Zhao Weilai made his final appearance and shared the Chinese experience of CAR-T treatment with colleagues around the world
.

Professor Zhao Weilai shared the treatment and management of two Chinese DLBCL patients receiving CAR-T cell therapy.
Through a comprehensive display of patient characteristics, treatment process, AE management after CAR-T, and efficacy evaluation, we can see CAR-T The excellent curative effect of treatment of lymphoma, the valuable Chinese experience in the whole process of CAR-T management, the current challenges and some effective coping strategies
.

A Chinese patient shared by Professor Zhao Weilai is a 57-year-old woman.
This patient is also the first patient to be enrolled in the pre-marketing registered clinical study in China.
The patient was diagnosed with Non-GCB DLBCL, Ann Arbor stage II, IPI score 2 points
.

After the diagnosis, the patient successively received multi-line treatments such as R-CHOP, R2-ICE and R2-GDP.
The disease progressed, so it was decided to try CAR-T immunotherapy
.

In the clinical study in November 2018, he received Akirensai injection (Axi-Cel) treatment.
After CAR-T reinfusion, the treatment effect was good.
The curative effect was evaluated as partial remission (PR) at 28 days after reinfusion, and the curative effect was 90 days.
It is assessed as complete remission (CR), and the patient’s complete remission status has been maintained for nearly 3 years so far
.

Another Chinese patient shared by Professor Zhao Weilai is a 76-year-old female diagnosed with Non-GCB DLBCL, Ann Arbor stage IIIA, IPI score of 2, and a previous history of Sjogren’s syndrome
.

The patient reached PR after 6 cycles of first-line R-CHOP treatment in February 2020, and BTKi+ICE was adopted for the second-line treatment, and the disease progressed
.

In June 2021, China's first CAR-T product, Akirensai injection, was launched, officially opening the first year of China's CAR-T cell therapy
.

Considering that the patient's condition is still difficult to control after the second-line treatment and is accompanied by Sjogren's syndrome, in July 2021, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine decided to give the patient CAR-T immunotherapy, and the patient was treated with mononuclear cell collection and bridging treatment After preparations such as cleansing and leaching, CAR-T cells were successfully transfused back
.

After AE management such as CRS, CLS, interstitial pneumonia, and NT, the patient is currently in a stable state, and was evaluated as CR by PET-CT on the 28th day after reinfusion, and is in good condition so far
.

Professor Zhao Weilai concluded that the real world situation is complex, the patient’s baseline status is different from clinical research, and there may be various other complications.
Clinical treatment needs to be individualized.
As long as the clinical management is proper, CAR-T therapy can also achieve better results.
The curative effect
.

The first two patients in Ruijin Hospital obtained CR, and other domestic hospitals have also reported CR results using Akilunza injection.
The good curative effect is really exciting
.

At the same time, Professor Zhao suggested that CAR-T real-world treatment should strengthen the development of MDT, identify CRS, NT and other AEs as soon as possible and actively respond to them to ensure that the safety is manageable and controllable
.

In recent years, the development of domestic CAR-T cell therapy can be said to be in full swing, and gratifying breakthroughs have been made in academic research and clinical practice.
I believe that with the unremitting efforts of Chinese blood workers, CAR-T cell therapy in China will surely increase in the future.
Perfect and standardized, the vast number of patients with malignant hematological tumors can also reap the good hope of curing the disease
.

Professor Zhao Weilai Chief Physician, Professor, Doctoral Supervisor, Ministry of Education, Yangtze River Scholar, Distinguished Professor, National Outstanding Youth Science Fund Winner, Ministry of Science and Technology, Ten Thousand Thousand Talents Program, National Talent Project, National Candidate, Shanghai Jiaotong University School of Medicine, Ruijin Hospital, Shanghai Executive Deputy Director, Institute of Hematology, Executive Deputy Director, Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Deputy Director, Hematology Branch of Chinese Medical Association, Deputy Leader of Lymphocytic Diseases Group, Deputy Leader of Laboratory Diagnostics Group, Chinese Pathophysiology Member of the Society Secretary-General of the Chinese Society of Experimental Hematology, Member of the Standing Committee, Vice-Chairman of the Anti-Lymphoma Alliance of the Chinese Clinical Tumor Association, stamp "read the original text", we will make progress together